GBCAs are routinely used in many clinical MRI protocols, their high stability should ensure that the Gd-complexes are excreted intact without side effects. Recently, it was reported that tiny amounts of Gd3+ may be retained in the brain of patients. The aim of this study was to investigate, in an animal model, the in vivo fate of Gadoteridol and Gadodiamide extending the investigation of Gd retention to other body tissues besides brain. Several administration protocols differing for i) the number of total doses, ii) the frequency of the administrations and iii) the sacrifice time after the last administration, were compared.
This abstract and the presentation materials are available to members only; a login is required.